ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and ... MarketWatch (press release) Phase II trials are now in process that evaluate SAR3419: (1) as a single agent for diffuse large B-cell lymphoma (DLBCL); (2) in combination with Rituxan(R) (rituximab) for DLBCL; and (3) as a single agent for B-cell acute lymphoblastic leukemia ... |
